PURE Bioscience, Inc. (PURE)
OTCMKTS · Delayed Price · Currency is USD
0.0700
0.00 (0.00%)
At close: Nov 13, 2026
PURE Bioscience Balance Sheet
Financials in millions USD. Fiscal year is August - July.
Millions USD. Fiscal year is Aug - Jul.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 |
Cash & Equivalents | 0.57 | 0.33 | 0.35 | 1.1 | 3.39 |
Cash & Short-Term Investments | 0.57 | 0.33 | 0.35 | 1.1 | 3.39 |
Cash Growth | 70.36% | -4.30% | -68.13% | -67.71% | 41.88% |
Receivables | 0.33 | 0.47 | 0.3 | 0.29 | 0.2 |
Inventory | 0.19 | 0.14 | 0.06 | 0.09 | 0.18 |
Prepaid Expenses | 0.01 | 0.02 | 0.03 | 0.06 | 0.02 |
Restricted Cash | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 |
Total Current Assets | 1.19 | 1.05 | 0.81 | 1.6 | 3.86 |
Property, Plant & Equipment | 0.01 | 0.01 | 0.01 | 0.22 | 0.62 |
Total Assets | 1.19 | 1.06 | 0.82 | 1.83 | 4.48 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 |
Accounts Payable | 0.82 | 0.78 | 0.6 | 0.42 | 0.49 |
Accrued Expenses | 0.17 | 0.15 | 0.13 | 0.11 | 0.09 |
Current Portion of Long-Term Debt | 3.38 | 1.18 | - | - | - |
Total Current Liabilities | 4.37 | 2.11 | 0.73 | 0.53 | 0.58 |
Long-Term Debt | 3.22 | 4.06 | 2.95 | 1.02 | - |
Total Liabilities | 7.59 | 6.17 | 3.68 | 1.55 | 0.58 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 |
Common Stock | 1.3 | 1.12 | 1.12 | 1.12 | 1.11 |
Additional Paid-In Capital | 133.78 | 132.76 | 132.61 | 132.4 | 132.08 |
Retained Earnings | -141.48 | -138.99 | -136.6 | -133.25 | -129.28 |
Shareholders' Equity | -6.4 | -5.12 | -2.86 | 0.27 | 3.91 |
Total Liabilities & Equity | 1.19 | 1.06 | 0.82 | 1.83 | 4.48 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 |
Total Debt | 6.6 | 5.24 | 2.95 | 1.02 | - |
Net Cash (Debt) | -6.03 | -4.9 | -2.6 | 0.07 | 3.39 |
Net Cash Growth | - | - | - | -97.82% | 57.65% |
Net Cash Per Share | -0.05 | -0.04 | -0.02 | 0.00 | 0.04 |
Filing Date Shares Outstanding | 140.2 | 111.89 | 111.86 | 111.86 | 111.36 |
Total Common Shares Outstanding | 130.02 | 111.89 | 111.86 | 111.86 | 111.36 |
Working Capital | -3.19 | -1.07 | 0.07 | 1.07 | 3.29 |
Book Value Per Share | -0.05 | -0.05 | -0.03 | 0.00 | 0.04 |
Tangible Book Value | -6.4 | -5.12 | -2.86 | 0.27 | 3.91 |
Tangible Book Value Per Share | -0.05 | -0.05 | -0.03 | 0.00 | 0.04 |
Machinery | 1.62 | 1.62 | 1.62 | 1.62 | 1.58 |
Construction In Progress | - | - | - | - | 0.08 |